A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC
Clinical trial NCT05106335 · TERMINATED
Trial details
- NCT number
- NCT05106335
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-06
- Primary completion
- 2022-05-11
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.